Spruce Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Spruce Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-105.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 84% of Healthcare companies in United States.
Cash Cushion Ratio
+36%Cash, after subtracting all debt, equals 36% of its market value (net cash).
Higher than 72% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Spruce Biosciences, Inc. made a loss over the last year. Spruce Biosciences, Inc. owes $0.19 for every $1 it owns. Spruce Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSpruce Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.55The share price is 1.55 times Spruce Biosciences, Inc.'s book value per share, lower than 66% of Healthcare companies in United States.
Market cap
$130 MThe total market value of all of Spruce Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$84 MWhat Spruce Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$29.13Net worth divided by the number of shares. The share price of $45.15 is 1.5 times this, which is the P/B above.
Return on equity (ROE)
-106.0%Spruce Biosciences, Inc. lost 106.0% of its shareholders' money over the last year, lower than 72% of Healthcare companies in United States.
Owes vs Owns
0.19×Spruce Biosciences, Inc. owes $0.19 for every $1 it owns (low), lower than 75% of Healthcare companies in United States.
Dividend yield
NoneSpruce Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossSpruce Biosciences, Inc. made a loss in each of the last two years.
Interest cover
Not coveredSpruce Biosciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashSpruce Biosciences, Inc. held $48 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Spruce Biosciences, Inc.: $130 M ÷ $84 M (30 Jun 2026) = 1.5.
What is Spruce Biosciences, Inc.'s return on equity?
Spruce Biosciences, Inc. lost 106.0% of its shareholders' money over the last year, lower than 72% of Healthcare companies in United States.
How much does Spruce Biosciences, Inc. owe compared with what it owns?
Spruce Biosciences, Inc. owes $0.19 for every $1 it owns (low), lower than 75% of Healthcare companies in United States.
Does Spruce Biosciences, Inc. pay a dividend?
No. Spruce Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.